ArticleDrug delivery2019
Cetuximab-modified silica nanoparticle loaded with ICG for tumor-targeted combinational therapy of breast cancer.
Article in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 74 citations in OpenAlex.
- Synthesis and molecular characterization of a novel FA-ADH-GMS conjugated pH-responsive lipid for targeted drug delivery.Molecular diversity · 2026Article
- Design and Synthesis of Peptide-Tagged Cubosome Nanocarriers for the Targeted Delivery of Paclitaxel in EGFR Overexpressing Breast Cancer.ACS biomaterials science & engineering · 2026Article
- A novel EGFR-targeted photosensitizer for the theranostics of skin cancer.International journal of pharmaceutics: X · 2025Article
- Nano-carrier, design, synthesis, in silico ADMET, anti-proliferative assessments and docking of [1,2,4]triazolo[4,3-a]quinoxalines as Topo-II inhibitors and DNA intercalators.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Design, nanogel synthesis, anti-proliferative activity andRSC advances · 2025Article
- "On-demand" nanosystem-integrated microneedles for amplified triple therapy against recalcitrant bacteria and biofilm growth.Materials today. Bio · 2024Article
- From bone to nanoparticles: development of a novel generation of bone derived nanoparticles for image guided orthopedic regeneration.Biomaterials science · 2024Article
- Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials.Journal of nanobiotechnology · 2024Review
- Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers.Pharmaceutics · 2024Review
- Review
- Secretome analysis of breast cancer cells to identify potential target proteins ofFrontiers in cell and developmental biology · 2023Article
- Magnetoelectric core-shell CoFeRSC advances · 2022Article
- Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties.Molecules (Basel, Switzerland) · 2022Review
- Drug Delivery Based on Stimuli-Responsive Injectable Hydrogels for Breast Cancer Therapy: A Review.Gels (Basel, Switzerland) · 2022Review
- Indocyanine green as a near-infrared theranostic agent for ferroptosis and apoptosis-based, photothermal, and photodynamic cancer therapy.Frontiers in molecular biosciences · 2022Article
- One-pot synthesis chlorin e6 nano-precipitation for colorectal cancer treatment Ce6 NPs for colorectal cancer treatment.IET nanobiotechnology · 2021Article
- Co-delivery of cisplatin and oleanolic acid by silica nanoparticles-enhanced apoptosis and reverse multidrug resistance in lung cancer.The Kaohsiung journal of medical sciences · 2021Article
- Temperature and pH Dual Responsive Nanogels of Modified Sodium Alginate and NIPAM for Berberine Loading and Release.ACS omega · 2021Article
- Article
- Nucleus-Targeted Photosensitizer Nanoparticles for Photothermal and Photodynamic Therapy of Breast Carcinoma.International journal of nanomedicine · 2021Article
Corrections and comments
- Erratum issuedCorrection.2019
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combinational therapy is usually considered as a preferable approach for effective cancer therapy. Especially, combinational chemo and photothermal therapy is of particular interest due to its high flexibility as well as efficiency. In this article, we the silica nanoparticles (SLN) were surface conjugated with Cetuximab (Cet-SLN) to target epidermal growth factor receptor (EGFR), a common receptor that usually observed to overexpress in multiple breast cancers. Moreover, the high drug loading capacity of Cet-SLN was employed to encapsulate photothermal agent indocyanine green (ICG) to finally fabricate a versatile drug delivery system (DDS) able to co-deliver Cet and ICG (Cet-SLN/ICG) for combinational chemo-photothermal therapy of breast cancer. The obtained results clearly demonstrated that Cet-SLN/ICG was well-dispersed nanoparticles with preferable stability under physiological condition. Furthermore, due to the conjugation of Cet, Cet-SLN/ICG could target EGFR which overexpress in MCF-7 cells. Most importantly, both in vitro and in vivo results suggested that compared with Cet or ICG alone, the Cet-SLN/ICG showed superior anticancer efficacy. In conclusion, Cet-SLN/ICG could be a potential platform for effective combinational chemo-photothermal therapy for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.